Free Trial

MIRA Pharmaceuticals 11/12/2024 Earnings Report

MIRA Pharmaceuticals logo
$0.86 -0.04 (-4.44%)
As of 11:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

MIRA Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MIRA Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Remove Ads

MIRA Pharmaceuticals Earnings Headlines

What is Zacks Small Cap's Estimate for MIRA FY2026 Earnings?
Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
MIRA Enrolls Patients Amid Rapid Progress
See More MIRA Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MIRA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MIRA Pharmaceuticals and other key companies, straight to your email.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals (NASDAQ:MIRA) operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

View MIRA Pharmaceuticals Profile

More Earnings Resources from MarketBeat